Financial
-
New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung cancer who have a MET positive biomarker had an overall response rate of 61 percent and a median PFS of 12.2 months when treated with the chemotherapy-free combination of RYBREVANT® and lazertinib Updated safety analysis from the Phase 1 PALOMA study evaluating subcutaneous delivery of RYBREVANT® showed shorter administration time and a marked reduction in the incidence and severity of infusion-related reactions -
-
-
-
-
-
-
Johnson & Johnson Reports Q1 2023 Results
2023 First-Quarter reported sales growth of 5.6% to $24.7 Billion with operational growth of 9.0%* and adjusted operational growth of 7.6%* 2023 First-Quarter basic loss per share of ($0.03) decreasing 101.6% due to a special one-time charge, with adjusted earnings per share (EPS) of $2.68 increasing by 0.4%* Company is increasing 2023 full-year guidance midpoints for adjusted operational sales and adjusted operational EPS -